Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
View Patent ↗Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
1. A pharmaceutical composition comprising:
(a) about 3 to 20% by weight of sitagliptin, or a pharmaceutically acceptable salt thereof;
(b) about 25 to 94% by weight of metformin hydrochloride;
(c) about 0.1 to 10% by weight of a lubricant;
(d) about 0 to 35% by weight of a binding agent;
(e) about 0.5 to 1% by weight of a surfactant; and
(f) about 5 to 15% by weight of a diluent.
2. The pharmaceutical composition of claim 1 additionally comprising one or more excipients selected from the group consisting of (a) a disintegrant; (b) a wetting agent; and (c) an anti-oxidant.
3. The pharmaceutical composition of claim 1 comprising:
(a) about 5 to 18% by weight of sitagliptin, or a pharmaceutically acceptable salt thereof;
(b) about 65 to 77% by weight of metformin hydrochloride;
(c) about 1 to 2% by weight of a lubricant;
(d) about 4 to 9% by weight of a binding agent;
(e) about 0.5 to 1% by weight of a surfactant; and
(f) about 5 to 15% by weight of a diluent.
4. The pharmaceutical composition of claim 3 wherein said lubricant is magnesium stearate or sodium stearyl fumarate, and the binding agent is polyvinylpyrrolidone.
5. The pharmaceutical composition of claim 3 comprising:
(a) about 9% by weight of sitagliptin, or a pharmaceutically acceptable salt thereof;
(b) about 73% by weight of metformin hydrochloride;
(c) about 1 to 2% by weight of a lubricant;
(d) about 7% by weight of a binding agent;
(e) about 0.5 to 1% by weight of a surfactant; and
(f) about 5 to 15% by weight of a diluent.
6. The pharmaceutical composition of claim 5 additionally comprising about 0.5% by weight of a surfactant and about 10% by weight of a diluent.
7. The pharmaceutical composition of claim 3 comprising
(a) about 5% by weight of sitagliptin, or a pharmaceutically acceptable salt thereof;
(b) about 77% by weight of metformin hydrochloride;
(c) about 1 to 2% by weight of a lubricant;
(d) about 7% by weight of a binding agent;
(e) about 0.5 to 1% by weight of a surfactant; and
(f) about 5 to 15% by weight of a diluent.
8. The pharmaceutical composition of claim 7 additionally comprising about 0.5% by weight of a surfactant and about 10% by weight of a diluent.
9. The pharmaceutical composition of claim 1 wherein the salt is the dihydrogenphosphate salt.
10. A pharmaceutical composition comprising:
(a) sitagliptin present in a unit dosage strength of 25 to 200 milligrams;
(b) metformin hydrochloride present in a unit dosage strength of 250, 500, 625, 750, 850, or 1000 milligrams;
(c) about 1 to 2% by weight of a lubricant;
(d) about 7% by weight of a binding agent;
(e) about 10% by weight of a diluent; and
(f) about 0.5% by weight of a surfactant.
11. The pharmaceutical composition of claim 10 wherein said lubricant is sodium stearyl fumarate, said binding agent is polyvinylpyrrolidone, said diluent is microcrystalline cellulose, and said surfactant is sodium lauryl sulfate.
12. The pharmaceutical composition of claim 10 wherein sitagliptin is present in a unit dosage strength of 25, 50, 75, 100, 150, or 200 milligrams, and said metformin hydrochloride is present in a unit dosage strength of 500, 850, or 1000 milligrams.
13. The pharmaceutical composition of claim 12 wherein sitagliptin is present in a unit dosage strength of 50 milligrams, and said metformin hydrochloride is present in a unit dosage strength of 500, 850, or 1000 milligrams.
14. The pharmaceutical composition of claim 12 wherein said sitagliptin is present in a unit dosage strength of 50 milligrams, and said metformin hydrochloride is present in a unit dosage strength of 500 or 1000 milligrams.
15. The pharmaceutical composition of claim 1 wherein said composition is in the dosage form of a tablet.
16. A method of treating Type 2 diabetes in a human in need thereof comprising orally administering to said human a pharmaceutical composition of claim 1 .
17. The pharmaceutical composition of claim 1 further comprising one or more agents selected from the group consisting of flavoring agents, colorants, and sweeteners.
18. The pharmaceutical composition of claim 1 prepared by wet granulation methods.
19. The pharmaceutical composition of claim 12 wherein said composition is in the dosage form of a tablet.
20. A method of treating Type 2 diabetes in a human in need thereof comprising orally administering to said human a pharmaceutical composition of claim 12 .
21. A pharmaceutical composition consisting essentially of:
(a) about 3 to 20% by weight of sitagliptin, or a pharmaceutically acceptable salt thereof;
(b) about 25 to 94% by weight of metformin hydrochloride;
(c) about 0.1 to 10% by weight of a lubricant;
(d) about 0 to 35% by weight of a binding agent;
(e) about 0.5 to 1% by weight of a surfactant; and
(f) about 5 to 15% by weight of a diluent.
22. A pharmaceutical composition in the form of a tablet comprising:
a) 64.25 mg[*] of sitagliptin phosphate monohydrate, which is equivalent to 50 mg of sitagliptin free base anhydrate;
b) 500 mg of metformin hydrochloride;
c) 48.2 mg of polyvinylpyrrolidone;
d) 3.45 mg of sodium lauryl sulfate;
e) 59.3 mg of microcrystalline cellulose;
f) 13.8 mg of sodium stearyl fumarate; and
g) 17.2 mg of a film coating.
23. A pharmaceutical composition in the form of a tablet comprising:
a) 64.25 mg[*] of sitagliptin phosphate monohydrate, which is equivalent to 50 mg of sitagliptin free base anhydrate;
b) 850 mg of metformin hydrochloride;
c) 78.2 mg of polyvinylpyrrolidone;
d) 5.60 mg of sodium lauryl sulfate;
e) 96.1 mg of microcrystalline cellulose;
f) 22.3 mg of sodium stearyl fumarate; and
g) 27.9 mg of a film coating.
24. A pharmaceutical composition in the form of a tablet comprising:
a) 64.25 mg[*] of sitagliptin phosphate monohydrate, which is equivalent to 50 mg of sitagliptin free base anhydrate;
b) 1000 mg of metformin hydrochloride;
c) 91.0 mg of polyvinylpyrrolidone;
d) 6.50 mg of sodium lauryl sulfate;
e) 112.3 mg of microcrystalline cellulose;
f) 26 mg of sodium stearyl fumarate; and
g) 32.5 mg of a film coating.
25. A pharmaceutical composition in the form of a tablet comprising:
a) 64.25 mg[*] of sitagliptin phosphate monohydrate, which is equivalent to 50 mg of sitagliptin free base anhydrite;
b) 500 mg of metformin hydrochloride;
c) 48.2 mg of polyvinylpyrrolidone;
d) 69.6 mg of microcrystalline cellulose;
e) 6.89 mg of magnesium stearate; and
f) 17.2 mg of a film coating.
26. A pharmaceutical composition in the form of a tablet comprising:
a) 64.25 mg[*] of sitagliptin phosphate monohydrate, which is equivalent to 50 mg of sitagliptin free base anhydrite;
b) 1000 mg of metformin hydrochloride;
c) 91.0 mg of polyvinylpyrrolidone;
d) 125.25 mg of microcrystalline cellulose;
e) 13.0 mg of magnesium stearate;
f) 6.5 mg of sodium lauryl sulfate; and
g) 32.5 mg of a film coating.
27. A pharmaceutical composition in the form of a tablet comprising:
a) 128.5 mg[*] of sitagliptin phosphate monohydrate, which is equivalent to 100 mg of sitagliptin free base anhydrite;
b) 1000 mg of metformin hydrochloride;
c) 91.0 mg of polyvinylpyrrolidone;
d) 6.50 mg of sodium lauryl sulfate;
e) 48 mg of microcrystalline cellulose; and
f) 26 mg of sodium stearyl fumarate.
28. A pharmaceutical composition in the form of a tablet comprising:
a) 128.5 mg[*] of sitagliptin phosphate monohydrate, which is equivalent to 100 mg of sitagliptin free base anhydrate;
b) 500 mg of metformin hydrochloride;
c) 53.8 mg of polyvinylpyrrolidone;
d) 3.84 mg of sodium lauryl sulfate;
e) 66.5 mg of microcrystalline cellulose; and
f) 15.4 mg of sodium stearyl fumarate.